Akin to TG2 in CD, TG6, a TG isozyme specifically expressed in the brain, has been suggested to be the primary autoantigen in GA,6 and the presence of circulating anti-TG6 antibodies is a potential biomarker for GA.23,24 Furthermore, adherence to a gluten-free diet (GFD), the main therapeutic strategy currently available for patients, is associated with reduced antibody titres24 and improvement of ataxia symptoms.25 Here, TGM6 is linked to Ataxia.